Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus

INTRODUCTION: This trial evaluated the safety, biologic activity, and pharmacokinetics of belimumab, a fully human monoclonal antibody that inhibits the biologic activity of the soluble form of the essential B-cell survival factor B-lymphocyte stimulator (BLyS) in patients with systemic lupus erythe...

Descripción completa

Detalles Bibliográficos
Autores principales: Furie, Richard, Stohl, William, Ginzler, Ellen M, Becker, Michael, Mishra, Nilamadhab, Chatham, Winn, Merrill, Joan T, Weinstein, Arthur, McCune, W Joseph, Zhong, John, Cai, Wendy, Freimuth, William
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2592791/
https://www.ncbi.nlm.nih.gov/pubmed/18786258
http://dx.doi.org/10.1186/ar2506

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2592791/
https://www.ncbi.nlm.nih.gov/pubmed/18786258
http://dx.doi.org/10.1186/ar2506

Ejemplares similares